Inhibition of VEGF activity or disabling the function of VEGF receptors is therefore a potential strategy for improving radiation outcome. The VEGF blockade alone has been shown to inhibit both tumor growth and metastasis in a variety of animal tumor models 11 . Currently, three approaches are in clinical development to target the VEGF/VEGFR-signaling pathway: (1) monoclonal antibodies directed against VEGF or its receptors [12] [13] [14] [15] , (2) small molecule inhibitors of the VEGFR-2 tyrosine kinase enzyme [16] [17] [18] [19] , and (3) soluble decoy receptors created from the VEGFR1 receptor which selectively inhibit VEGF 20, 21 . The relative benefits of these strategies have yet to be determined clinically. Tumor cures are rare when VEGF blockers are used as the sole method of treatment; in general, antiangiogenics appear to work best in combination with cytotoxic therapies 22 . A number of preclinical studies suggest that radiotherapy in combination with VEGF targeting agents enhances the radiotherapeutic ratio (see reviews; 23, 24 ). The best way to incorporate VEGF inhibition strategies into current radiotherapy regimens remains unknown.
Because of the role that angiogenesis plays in the radiation response, the objective of this study was to determine whether VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a potent anti-VEGF angiogenesis inhibitor that traps circulating VEGF in the bloodstream and in the extracellular space, would enhance radiation therapy in the human U87 glioblastoma (GBM) tumor model. Because GBM tumors are among the most radioresistant and vascular of neoplasms and are known to secrete high levels of VEGF 25 , U87 GBM was deemed an appropriate model to assess the effects of VEGF Trap and radiation. It was hypothesized that inhibition of VEGF signaling by VEGF Trap would improve the human U87 glioblastoma model response to radiotherapy.
The administration of decoy soluble VEGF receptors has been found to be a very effective way to block the VEGF signaling pathway [26] [27] [28] [29] . VEGF Trap is a unique human fusion protein comprising portions of human VEGF recep-
VEGF Trap In Combination With Radiotherapy Improves Tumor Control In U87 Glioblastoma
Purpose To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor (VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts in nude mice.
Methods and Materials
U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap (2.5-25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF Trap plus fractionated RT were examined.
Results
Improved tumor control was seen when RT (either single dose or fractionated doses) was combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly affect the efficacy of combined therapy. Although high-dose VEGF Trap (10 mg/kg or 25 mg/kg) significantly reduced tumor growth over that of RT alone, there was no additional benefit to combining high-dose VEGF Trap with RT.
Introduction
Radiation (RT) therapy is an important treatment modality for many cancers; however, its therapeutic success is impeded by dose-limiting normal tissue toxicities and the development of radioresistance. Recent studies emphasize the importance of the tumor microvascular response in addition to the tumor cell response in determining tumor radioresistance 1, 2 . Ionizing radiation can directly induce endothelial cell apoptosis 1, 3 , which can inhibit tumor growth and lead to radiosensitization. However, in opposition to endothelial cell damage, radiation also induces signal transduction cascades, which contribute to radiation resistance through upregulation of proliferative, survival, and angiogenic pathways 4 . In particular, radiation induces vascular cytokines, such as vascular endothelial growth factor (VEGF) 5, 6 , one of the most potent endothelial cell survival factors 7 , which functions as a powerful antiapoptotic factor for endothelial cells in new blood vessels 8, 9 . Radiation-induced VEGF results in tumor radioresistance through vascular radioprotection 2, 10 . Phyllis R. Wachsberger, PhD,* Randy Burd, PhD, § Chris Cardi, MS, tor 1 (VEGFR1) and human VEGF receptor 2 (VEGFR2) extracellular domains fused to the constant region (Fc) of human IgG1
21
. VEGF Trap has greater affinity for the VEGF ligand than anti-VEGF monoclonal antibodies (mab) do (dissociation constant <1 pMol/L for VEGF Trap vs. 0.1-10 nMol/L for mab) 30 . VEGF Trap has been shown to inhibit neoangiogenesis and tumor growth in tumor xenografts and metastases, as well as reduce the formation of malignant ascites 14, 21, 31 .
Methods and Materials
Analysis of VEGF levels in U87 tumor cells in culture U87 glioblastoma cells (American Type Culture Collection) were maintained in alpha MEM (Sigma-Aldrich, St. Louis, MO) with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA). U87 cells were irradiated at doses between 2 and 20 Gy in the presence or absence of 40 nM VEGF Trap and incubated for 48 h. Using a commercially available human VEGF immunoassay kit (R&D Systems, Minneapolis, MN), VEGF was assayed from culture supernatants.
Animal and tumor model U87 cell suspensions (5 x 10
5 cells in 100 μL phosphate buffered saline) were implanted subcutaneouly (SC) into the right hind limbs of athymic NCR NUM mice (Taconic Farms, Hudson, NY) . A SC xenograft model was chosen to facilitate radiation dosing and ease of tumor measurements in the more than 200 mice measured in this study. Mice were not pretreated before tumor implantation. U87 tumors were allowed to grow for approximately 14 to 18 days until reaching an approximate diameter of 4 to 5 mm before treatment.
Drug and irradiation treatment
In an initial pilot study, VEGF Trap was administered at two doses, a high dose (25 mg/kg) or low dose (2.5 mg/kg), every 3 days, up to 3 weeks, with or without a single dose of radiation (10 Gy) given on Day 0. VEGF Trap was administered every 3 days because it has a half-life of 72 h in mouse serum (drug pharmacokinetics communicated by Regeneron). Drug was administered 2 h before radiation. When fractionated radiotherapy was used, VEGF Trap was combined at 2.5 mg/kg (low dose) or 10 mg/kg (intermediate dose) with fractionated radiotherapy (three fractions of 5 Gy each) on Days 0, 1, and 2. Scheduling of VEGF Trap was either 1 week before fractionated radiation and continuing for a period of 3 weeks, concurrent with radiation and continuing for a period of 3 weeks, or 3 days postradiation treatment and continuing for a period of 3 weeks. Thus, the total number of drug doses was constant for each schedule (see Fig. 1 for dose and irradiation scheduling protocol).
Irradiation was performed on anesthetized mice using an X-ray machine (Gulmay Medical, Bethel, CT) operating at 250 kV, 10 mA, with a 2-mm aluminum filtration. The effective photon energy was ≈90 keV. Mice were anesthetized with a combination of ketamine and acepromazine at a concentration of 75 mg/kg and 0.35 mg/kg, respectively. Each mouse was confined in a lead casing with its tumor-bearing leg extended through an opening on the side to allow the tumor to be irradiated locally. Radiation was administered as three daily fractions of 5 Gy each as described earlier.
Tumor size was measured 4 to 5 times per week after treatment by direct measurement with calipers and calculated by the formula [(smallest diameter (2) x widest diameter) / 2]. Tumors were not allowed to grow beyond 2,000 mm 3 in accordance with Institutional Animal Care and Use Committee regulations.
Positron emission tomography imaging
The MOSAIC PET scanner (Philips Medical Systems, Brisbane, CA) was used for PET studies. Before imaging, mice were anesthetized with ketamine (75 mg/kg) and acepromazine (0.35 mg/kg) via a SC injection. Once anesthetized 0.3 to 0.5 μCi of 18-fluorodeoxyglucose (FDG) was administered intravenously. Sixty to seventy min were allowed for uptake of the tracer. Mice were placed in a 50-mL specimen tube to facilitate multimodality stereotactic positioning. The PET data were acquired in a single position for 15 min. Volumes of interest (VOIs) were defined by drawing multislice regions of interest (ROIs) on the PET images using 50% of the full-width-at-half-maximum (FWHM) of the tumor to determine the tumor boundary. In the case of tumors with a core lacking FDG uptake, the tumor and core boundaries were defined by 50% FWHM of each wall adjacent to the core. Mice were divided into three groups (n = 3-6 animals per group): untreated; low-dose VEGF Trap-treated (2.5 mg/kg), and highdose VEGF Trap-treated (10 mg/kg). Immunohistochemistry Platelet-endothelial cell adhesion molecule 1 (PECAM-1) immunostaining for microvessel density (MVD): control, radiation-treated, VEGF Trap-treated tumors, and VEGF Trap plus radiation-treated tumors were immunostained with a rat antimouse PECAM-1 mAb (BD Biosciences, Boston, MA) and a rabbit antirat biotinylated secondary antibody (Vector Labs, Burlingame, CA). Enhanced horseradish peroxidase-conjugated streptavidin and a substrate chromogen, AEC (3-amino-9-ethyl carbazole), were used to visualize the signal. (HIS-TOSTAIN-PLUS kit, Invitrogen, Carlsbad, CA); slides were examined with a Nikon Eclipse E600 microscope to calculate MVD, the area occupied by the PECAM-1-positive microvessels, and total tissue area per section were quantified using National Institute of Health Image J software. Microvessel density was expressed as percent area of blood vessels stained per tissue section. Areas of necrosis were excluded from calculations. Four or five high-power fields were identified on each section with three to four sections per tumor and two tumors per endpoint.
Statistical analysis of tumor growth
Tumor size measurements over time were obtained from the following groups: control; radiation alone; VEGF Trap, low dose (2.5 mg/kg), intermediate dose (10 mg/kg), or high dose (25 mg/kg); and the corresponding two radiation plus VEGF Trap combinations (n = 10-14 animals per group). Tumor growth over the entire study follow-up period was modeled via mixed-effects linear regression. This approach fits a "random" growth curve to each animal's data and then statistically "averages" these curves within each treatment group to estimate an overall "fixed effect" for each group. It also properly handles unbalanced data (i.e., different number of measurements for different animals) and takes into account the correlation of each animal's measurements over time. Because tumors typically grow exponentially, the base-10 logarithm of tumor volume was modeled as a function of time and treatment. The interpretation of the linear model for the log of tumor volume is in terms of geometric means and geometric mean ratios (while the usual interpretation of a regression model for an untransformed outcome is in terms of arithmetic means and mean differences). The fitted linear growth curves fitted the data well. In addition, an allowance was made for the variance of the random effects to differ across groups to account for the larger variability of measurements in certain treated groups. All statistical analyses were conducted in SAS 8.2 (SAS Institute, Cary, NC, 1999 -2001 .
The mixed-effects regression has multiple advantages over analyses of tumor growth delay that typically compare groups with respect to the average time it takes tumors to reach some arbitrary size (e.g., 2,000 mm3). First, mixed-effects regression yields more general parameters of interest, such as average daily tumor growth rate and doubling time. Second, it can investigate (if necessary) treatment interactions and nonlinear patterns of tumor growth. Finally, it is more efficient because it used the repeated tumor size measurements obtained over the entire study period.
Results

Effect of VEGF Trap and radiation on VEGF secretion in U87 cells in culture
Levels of VEGF increased in U87 culture supernatants in a dose-dependent manner following irradiation (Fig. 2) . The addition of VEGF Trap (40 nM) reduced free VEGF in the supernatant to undetectable levels.
Effect of VEGF Trap and radiation on U87 tumor growth inhibition
The linear models for the log-transformed tumor growth fitted the data quite well in all groups. The raw data for all treatment groups with regression lines are plotted in Figs. 3 through 6 with corresponding Tables 1 through 4. The average daily percent increase in tumor volume for the untreated control group was consistent across all protocols and ranged between 27% and 31%, corresponding to a tumor doubling time between 2.5 and 3.0 days (Tables 1-4 Table 1 presents tumor growth data based on the mixed-effects linear regression analysis described in Methods and Materials, and Fig. 3 presents the original animal data. In this experiment, a low dose of VEGF Trap (2.5 mg/kg) initiated concurrently with a single dose of 10 Gy was compared with a 10x higher dose of VEGF Trap (25 mg/kg) plus 10 Gy. The six groups are compared in terms of average daily tumor growth and doubling time. It can be seen from Table 1 and Fig. 3 that both lowdose and high-dose VEGF Trap were effective inhibitors of daily percent increase in tumor volume (%Δ = 15% and 5%, respectively, vs. 31% for controls, p = 0.001). Although low-dose VEGF Trap was not significantly better than 10-Gy treatment alone, the combination of low-dose VEGF Trap and 10 Gy slowed daily tumor growth (%Δ = 12% vs. 18% for 10 Gy alone and 15% for low VEGF Trap alone). Thus, a less than additive enhancement in tumor control over either modality alone was observed. High-dose VEGF Trap, as a single treatment modality, was highly effective in slowing daily percent increase in tumor volume (5% vs. 18% for 10 Gy). Its efficacy was not improved by the addition of 10 Gy. This study Individual mouse data for six treatment groups (n = 10-12 animals per group). VEGF Trap was given at 2.5 or 25 mg/kg starting on Day 0, concurrent with radiation and continuing every 3 days for 3 weeks (see schedule I, Fig. 1 ). Individual mouse data for 6 treatment groups (n = 10-14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day -7 and continuing every 3 days for 3 weeks (see schedule II, Fig. 2 ). Individual mouse data for six treatment groups (n = 10-14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 3 and continuing every 3 days for 3 weeks (see schedule IV, Fig. 4 ). Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
Effect of VEGF Trap and single dose radiation (10 Gy) on U87 tumor growth inhibition
suggests that low-dose VEGF Trap in combination with single-dose radiation has an enhanced effect on tumor cell kill. It was thought that this enhancement might be improved by varying dose and scheduling protocol. Additional studies were carried out in which low-dose VEGF Trap at 2.5 mg/kg was compared with an intermediate dose of 10 mg/kg (because VEGF Trap at 25 mg/kg appeared to have masked any additional benefit of radiation in enhancing tumor control) in combination with a more clinically relevant fractionated radiotherapy protocol. The results of these studies are reported in the following sections.
Effect of VEGF Trap and fractionated radiation on U87 tumor growth inhibition VEGF Trap given before fractionated radiation: in this protocol, VEGF Trap was administered 7 days before radiation. The analyses allowed for separate tumor growth rates in the first and second periods (preradiation: Days -7 to 0; postradiation: Days 0+) for the groups that received radiation. The study's main aim was to compare tumor growth rates across treatment groups in the latter period, when all treatments had been applied. Table 2 summarizes the results of the tumor growth modeling analyses during this main study phase, and Fig. 4 presents the original animal data. The low-dose VEGF Trap group (2.5 mg/kg every third day, starting at Day -7) demonstrated a reduction in daily percent increase in tumor volume (12% vs. 27% for control; p = 0.001) that was similar to the first single-dose radiation study, whereas the high-dose VEGF Trap group (10 mg/kg every third day, starting at Day -7) had an even stronger effect (7%) that, again, was similar in trend to the first study. In the radiation only group, tumor daily growth was slowed to 11% (p < 0.001 vs. control). Although low-dose VEGF Trap was comparable to radiation alone (p = 0.59), the combination of low-dose VEGF Trap with radiation (7% average daily percent increase in tumor volume, Table 1 ) was significantly better than either radiation alone (p = 0.036) or low-dose VEGF Trap alone (p < 0.005). The combination of high-dose VEGF Trap with radiation (5% average percent daily increase in tumor volume) was also significantly better than radiation alone (p = 0.002) but not significantly better than high dose VEGF Trap alone (p = 0.33).
VEGF Trap given concurrently with fractionated radiation: Table 3 summarizes the results of the tumor growth modeling analyses based on original animal data shown in Fig. 5 . High-dose VEGF Trap was significantly better than radiation in reducing daily percent increase in tumor volume (8.5% vs. 16.1% for radiation, p = 0.001). The combination of low-dose VEGF Trap with radiation (12% average daily increase in tumor volume) was significantly better than either radiation alone (p = 0.029) or low-dose VEGF Trap alone (p = 0.012). The combination of high-dose VEGF Trap (10 mg/kg) with radiation (7% average daily increase in tumor volume) was also significantly better than radiation alone (p = 0.001) but not high-dose VEGF Trap alone (p = 0.417).
VEGF Trap given postradiation: Table 4 summarizes the results of the tumor growth modeling analyses based on original animal data shown in Fig. 6 . The results of this schedule followed the same pattern as seen in the previous two schedules with fractionated radiation as well as the first experiment with single-dose radiation. The benefit of combining VEGF Trap with radiation compared with single-modality treatments was once again seen with low-dose VEGF Trap plus radiation. High-dose VEGF Trap at 10 mg/kg plus radiation significantly reduced percent daily increase in tumor volume when compared with radiation alone but was not significantly different from VEGF Trap alone (p = 0.187).
In summary, improved tumor control was seen when radiation (either single dose or fractionated doses) were combined with the lowest dose of VEGF Trap (2.5 mg/kg) used in these studies. Scheduling did not significantly affectthe efficacy of combined therapy. The relative benefits of combined low-dose VEGF Trap plus fractionated radiation relative to radiation as judged by percent reduction in average daily increase in tumor volume were 36% for VEGF Trap given before radiation, 27% for concurrent treatment, and 32% for drug given postradiation treatment. Although high-dose VEGF Trap (either 10 mg/kg or 25 mg/kg) significantly reduced tumor growth over that of radiation alone, there was no added benefit to combining high dose VEGF Trap with radiation.
Effect of VEGF Trap and radiation on microvessel density
Immunoassaying for endothelial cells with PECAM-1 revealed an inhibition of tumor angiogenesis 3 weeks after treatment with VEGF Trap or VEGF Trap and radiation. Tumor MVD was similar in the control and radiation-treated tumors. Tumor MVD in the VEGF Trap treated tumors was decreased to between 43% to 57% of control or radiationtreated tumors (p = 0.06). Tumor MVD in VEGF and radiation-treated groups decreased to between 15% and 30% of control or radiationtreated groups (p = 0.001) (Fig. 7) . There was no significant difference in MVD between high-dose VEGF Trap-treated with radiation vs. high dose VEGF Trap alone (p = 0.29). However, there was a significant difference in MVD between low-dose VEGF Trap-treated with radiation and low-dose VEGF Trap alone (p = 0.01, Fig. 8 ). Figure 9a illustrates a series of images from a representative, untreated mouse. Figure 9b 
18-fluorodeoxyglucose-PET imaging of VEGF Trap-treated tumors
Discussion
This work demonstrated that VEGF Trap alone is an effective dosedependent inhibitor of tumor growth in U87GBM. These findings agreed with previous studies of VEGF Trap in other preclinical animal models demonstrating efficacy in halting angiogenesis and shrinking tumors 30 . Because VEGF Trap was very potent by itself and could have potentially masked any additional benefits of radiation, both low-dose and high-dose scheduling of the drug were used with radiotherapy. In all scheduling protocols that were investigated, the combination of low-dose VEGF Trap with radiation was significantly better than either treatment modality alone. On the other hand, high-dose VEGF Trap was significantly better than radiation alone and therefore masked any additional benefit that may have resulted from combination therapy.
The benefit of combined treatment with low VEGF Trap and radiation relative to radiation alone was not influenced by scheduling protocol. This result was in contrast to earlier work demonstrating improved radiation response when a VEGFR2 blocker, DC101, was given 4 to 6 days before radiotherapy 32 . This earlier work suggested that tumor vasculature normalization occurred during pretreatment with the VEGFR2 blocker, a process in which pruning of immature and inefficient blood vessels occurs leading to improved tumor perfusion and oxygenation and improved radiation response. The current observations may reflect the absence of a normalization effect by VEGF Trap on U87 GBM vasculature or a missed window of opportunity for normalization because of the particular protocols used in this work. Because it is not known how tumor oxygenation levels may have varied throughout the course of combined treatment with VEGF Trap and radiation, additional studies are warranted to resolve the issue of normalization.
The observation that scheduling did not have an impact on efficacy of combined treatment with VEGF Trap and radiation in this study is also in contrast to recent studies in which VEGF blockade was obtained either by a VEGF receptor2 tyrosine kinase inhibitor, ZD6474, or indirectly by HIF-1 alpha blockade of VEGF secretion. In both these studies, optimal antitumor efficacy was obtained when VEGF blockers were sequenced following radiation 2, 33 . These studies suggested that prolonged suppression of radiation-induced angiogenesis account for enhanced efficacy of combined treatments with angiogenesis blockade and radiation. However, it is not clearly understood why there is a difference in the impact of scheduling among these agents.
This work is encouraging in that it demonstrates for the first time a benefit in combining VEGF Trap with ionizing radiation in a highly resistant GBM tumor model. VEGF Trap is a unique human fusion protein with very potent binding affinity for VEGF A isoforms as well as placental growth factor (PIGF) and is currently in clinical trials. Its affinity for VEGF is potentially 100-to 1,000-fold higher than existing VEGF monoclonal antibodies such as bevacizumab 34 . This high-affinity blockade of VEGF differentiates VEGF Trap from other anti-VEGF strategies and therefore gives this drug the potential to enhance combination modality treatment with lower dosing.
Mechanisms of enhanced U87 tumor control by combined therapy with VEGF Trap and radiation most likely include inhibition of radiationinduced angiogenesis by VEGF Trap sequestration of circulating VEGF in the bloodstream and in the extracellular tumor space resulting from radiation-induced secretion. Indeed, in this study, a radiation-dosedependent increase in VEGF secretion by U87 glioblastoma cells was observed and excess VEGF was bound in the presence of VEGF Trap. In addition, immunohistochemical findings indicated a reduction in MVD 3 weeks following treatment with VEGF Trap and radiation. Inhibition of radiation-induced angiogenesis was also observed indirectly through FDG-PET imaging, which revealed an increase in metabolically inactive tumor tissue after VEGF Trap treatment, possibly arising from the induction of tumor necrosis or apoptosis in the presence of angiogenesis inhibition. It is also of interest that in this study, a brief period of fraction- ) and days following start of treatment are indicated. Imaging was performed as described in Methods and Materials. The percent of metabolically inactive tumor (as measured by FDG uptake) was significantly less in untreated tumors than in tumors treated with 10 mg/kg VEGF Trap. ated radiotherapy with VEGF Trap resulted in tumor growth retardation but not remission. The lack of remission is probably related to continued production of VEGF after removal of drug and radiation and points to the need for chronic therapy with VEGF Trap, which is in agreement with what has been observed for the transient effects of other antiangiogenic agents on tumor control 23, 35 .
In conclusion, these studies demonstrate that the combination of lowdose VEGF Trap and radiation is clearly better than radiation alone in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly efficacious, it is unclear whether such high doses can be used clinically without incurring normal tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation are of clinical relevance.
It is understood that the SC xenograft model used in this study has shortcomings in that ectopic tumors implanted SC in the hind limb of animals do not duplicate the vascular microenvironment of orthotopic brain implants 36 . However, the use of hind limb injection is the standard approach for xenograft studies with radiation. In addition, human xenografts in immunocompromised nude mice, whether they be ectopic or orthotopic, both have deficiencies in that they can only approximate the human patient situation and seldom reflect accurately the glioblastoma multiforme histopathology seen in patients. This study is encouraging in that it demonstrates for the first time a benefit in combining VEGF Trap with ionizing radiation and warrants further investigations both preclinically and clinically.
